These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27025906)

  • 1. Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma.
    Yonekura K; Tokunaga M; Kawakami N; Takeda K; Kanzaki T; Nakano N; Kubota A; Takeuchi S; Takatsuka Y; Seto M; Utsunomiya A
    Acta Derm Venereol; 2016 Nov; 96(7):1000-1002. PubMed ID: 27025906
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
    Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
    Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
    [No Abstract]   [Full Text] [Related]  

  • 4. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
    Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
    Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Tokunaga M; Yonekura K; Nakamura D; Haraguchi K; Tabuchi T; Fujino S; Hayashida M; Maekawa K; Arai A; Nakano N; Kamada Y; Kubota A; Inoue H; Owatari S; Takeuchi S; Takatsuka Y; Otsuka M; Hanada S; Matsumoto T; Yoshimitsu M; Ishitsuka K; Utsunomiya A
    Br J Haematol; 2018 May; 181(4):539-542. PubMed ID: 28369823
    [No Abstract]   [Full Text] [Related]  

  • 6. Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
    Miyagawa F; Yamamoto S; Miyao M; Nishikawa M; Ogawa K; Asada H
    Eur J Dermatol; 2018 Aug; 28(4):526-528. PubMed ID: 29952299
    [No Abstract]   [Full Text] [Related]  

  • 7. CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia/lymphoma.
    Tani N; Sugita K; Ito A; Ooi S; Yamamoto O
    Clin Exp Dermatol; 2018 Aug; 43(6):736-737. PubMed ID: 29744911
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study.
    Maemoto H; Ariga T; Kusada T; Heianna J; Manabe Y; Miyakawa A; Nakachi S; Morishima S; Iraha S; Ganaha F; Masuzaki H; Murayama S
    Jpn J Clin Oncol; 2019 Feb; 49(2):153-159. PubMed ID: 30452692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
    Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
    Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 11. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
    Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
    Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
    Morichika K; Tomoyose T; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Nishi Y; Nakachi S; Karube KN; Fukushima T; Katoh T; Ohshima K; Masuzaki H
    Intern Med; 2016; 55(10):1345-9. PubMed ID: 27181545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
    Kanno K; Honma M; Ishida-Yamamoto A
    J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
    [No Abstract]   [Full Text] [Related]  

  • 17. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
    Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypersensitivity reaction to β-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab
.
    Yasu T; Imai Y; Ohno N; Uchimaru K; Kurokawa Y; Tojo A
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):807-810. PubMed ID: 28793956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
    Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.